Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2025
0mins
Should l Buy ?
Source: Globenewswire
FDA Designation: Quoin Pharmaceuticals has received Rare Pediatric Disease Designation from the FDA for its lead asset QRX003, aimed at treating Netherton Syndrome, a severe genetic disorder affecting children.
Clinical Development Focus: The company is committed to advancing QRX003 towards a New Drug Application, supported by promising efficacy data and safety profiles, while also addressing other rare diseases in its pipeline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
